Horizon Europe · Europäische Union

Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers

Öffnet am 10. Februar 2027

Das EU-Programm Horizon Europe plant 3 Förderungen mit 7 Mio. € – 10 Mio. € pro Projekt bei einem Gesamtbudget von 20 Mio. €. Die Einreichungsfrist endet am 16. September 2027 (EU-Ausschreibungen enden meist um 17:00 Uhr Brüsseler Zeit). Organisationen aus EU-Mitgliedstaaten und assoziierten Ländern wie der Türkei können in der Regel teilnehmen; maßgeblich sind die Bedingungen des Topics.

Frist: 16. September 2027 (in 305 Tagen)
Öffnet: 10. Februar 2027
Fördersumme: 7 Mio. € – 10 Mio. € pro Projekt
Gesamtbudget: 20 Mio. €
Förderquote: 70 % für Unternehmen, 100 % für gemeinnützige Einrichtungen Standardregel des Programms; die Ausschreibung kann abweichen.
Gesamtbudget: 20 Mio. €
Erwartete Förderungen: 3
Maßnahmentyp: HORIZON Innovation Actions · HORIZON Lump Sum Grant
Wahrscheinliche Antragstellende: Unternehmen, KMU / Start-ups, Gemeinnützige, Hochschulen & Forschung, Öffentliche Stellen Aus Quellkategorien oder Programmregeln; maßgeblich ist die Ausschreibung.
Fördergeber: Horizon Europe (HORIZON)
Referenz: HORIZON-MISS-2027-02-CANCER-02
Ausschreibung: HORIZON-MISS-2027-02
Zuletzt geprüft: 14. November 2026

Offizielle Ausschreibung öffnen ↗ Frist zum Kalender hinzufügen

Die offiziellen Beschreibungen sind in der Sprache des Fördergebers (meist Englisch); Zusammenfassung und Eckdaten auf dieser Seite sind auf Deutsch.

Erwartete Ergebnisse

Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:

• Patients afflicted by lung, bowel, breast or prostate cancer [1] , will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer infrastructures [2] .

• Researchers, physicians, patient representatives, civil society, charities, foundations, insurance companies, SMEs and innovators [3] will seize opportunities to respectively co-create, support, upscale or commercialise outcomes of evidence-based, tailored, affordable and accessible clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.

• National and regional healthcare providers, healthcare payers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to engage in piloting, upscaling or implementing appropriate clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.

Umfang

Lung, bowel, breast and prostate cancer incidence, mortality and prevalence across EU Member States and Associated Countries are increasing while showing substantial variation, with Central and Eastern European communities, regions and countries particularly affected [4] . At the same time, the level of development of comprehensive cancer infrastructures continues to vary considerably across EU Member States and Associated Countries, contributing to inequalities, in particular in terms of clinical research capacity as well as quality of and access to innovative diagnostic and therapeutic interventions.

Applicants should address all of the following:

• Comprehensive cancer infrastructures across the EU Member States and Associated Countries come together to conduct clinical research on lung, bowel, breast or prostate cancer focusing on at least one of the following areas:

• Innovative diagnostics;

Vollständigen Text lesen

• Radiotherapy, surgery, chemotherapy;

• Therapeutic cancer vaccines for the treatment of cancer patients with early-stage, advanced, metastatic or minimal residual disease (e.g. after debulking by surgery, chemotherapy, radiotherapy, or immunotherapy);

• Implementation of appropriate clinical practice guidelines for diagnosis and treatment in countries without or with limited Comprehensive Cancer Infrastructures;

• Comprehensive cancer infrastructures should extensively pilot and upscale innovative diagnostic or treatment programmes in at least four different EU Member States or Associated Countries. One of the four targeted EU Member States or Associated Countries should represent a country without or with a less developed comprehensive cancer infrastructure.

• To ensure that together they address - and whenever feasible - overcome challenges because of the national, regional, or local research and healthcare context (e.g. those faced by small(er) EU Member States, or due to a large rural population, or particular cancer burden, socio-economic or environmental situation, or limited clinical research capacity [5] ), when designing and conducting innovative clinical research programmes with added value for the timely diagnosis and treatment of patients with lung, bowel, breast or prostate cancer;

• Identify additional resources through the European Regional Development Fund (ERDF), the Technical Support Instrument [6] , the Resilience and Recovery Facility (RRF), philanthropy, the European Investment Bank Group (EIB [7] , EIF [8] ) or any other initiative;

• Innovative clinical research programmes should be defined together with patients and their caregivers/families using participative research models and adapted to the needs of the target population and the specificities of healthcare provision at local, regional, or national level, duly reflecting the (cultural) diversity and available resources across EU Member States and Associated Countries;

• Data should be disaggregated by sex, gender, age and other relevant variables, such as by measures of…

Wer kann sich bewerben?

Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).

Antragstellerkategorien sind nur ein Ausgangspunkt. Über die Antragsberechtigung entscheidet die offizielle Ausschreibung.

Themen

Anticancer therapy Clinical medicine Digital data Gender in basic medicine Personalised medicine Radiology, nuclear medicine and medical imaging Translational medicine Cancer centre Clinical Trial Centre Comprehensive Cancer Centre Diagnostic facilities Hospital Medical Centre Oncology Department

Zeitplan

Single-stage call. Next deadline 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).

So bewerben Sie sich

Lesen Sie das vollständige Topic im Portal: erwartete Ergebnisse, Umfang, Maßnahmentyp und die Teilnahmebedingungen einschließlich Länder- oder Konsortialvorgaben.
Registrieren Sie jede Partnerorganisation im EU Funding & Tenders Portal, um einen PIC zu erhalten.
Verbundprojekte in Forschung und Innovation benötigen in der Regel mindestens drei unabhängige Partner aus drei verschiedenen EU-Mitgliedstaaten oder assoziierten Ländern. Prüfen Sie die Regel für dieses Topic.
Bereiten Sie Teil A (Verwaltungsformulare und Budget im Portal) und Teil B (technische Beschreibung auf der offiziellen Vorlage für diesen Maßnahmentyp) vor.
Reichen Sie vor dem Fristende am Stichtag im Portal ein. Verspätete Anträge werden nicht angenommen.

From the call text

Who can apply: Not stated in the call text we hold — check the official page
Company stage: Not stated in the call text we hold — check the official page
Single applicant or consortium: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where applicants must be based: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where to apply: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

EU-Leitfaden zur Antragstellung lesen

Offizielle Quellen

Offizielle Ausschreibungsseite

Die Angaben auf dieser Seite stammen aus der offiziellen Quelle und wurden zuletzt am 14. November 2026 geprüft. Maßgeblich sind immer die Unterlagen des Fördergebers einschließlich späterer Änderungen.